Segraves Justin M, Cartin-Ceba Rodrigo, Leise Michael D, Krowka Michael J
Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Department of Pulmonary and Critical Care Medicine, Mayo Clinic, Scottsdale, Arizona, USA.
Hepatol Res. 2018 Feb;48(3):E340-E346. doi: 10.1111/hepr.12930. Epub 2017 Aug 31.
Portopulmonary hypertension is a serious complication of portal hypertension that can lead to right heart failure and death. To our knowledge, an association between portopulmonary hypertension and prior splenectomy has not been described previously. The goals of this study were to describe the frequency of splenectomy in portopulmonary hypertension and compare selected parameters between portopulmonary hypertension subgroups.
This is a retrospective analysis of patients diagnosed with portopulmonary hypertension between 1 January 1988 and 30 June 2015 at Mayo Clinic (Rochester, MN, USA). We compared age, sex, right ventricle systolic pressure by echocardiography, and right heart catheterization measurements/calculations among subgroups of portopulmonary hypertension patients with splenectomy and/or autoimmune liver disease (autoimmune hepatitis/primary biliary cirrhosis/primary sclerosing cholangitis).
The cohort consisted of 141 patients, of whom 8 (6%) had a history of splenectomy prior to the development of portopulmonary hypertension. Twenty-seven (19%) portopulmonary hypertension patients had autoimmune liver disease, and 5 of 8 (62.5%) splenectomized portopulmonary hypertension patients had autoimmune liver disease. No significant difference was noted in right heart catheterization measurements/calculations between splenectomized and non-splenectomized portopulmonary hypertension patients. Right ventricle systolic pressure by echocardiography was significantly higher in those splenectomized.
Prior history of splenectomy in portopulmonary hypertension was 6% in this cohort. The combination of autoimmune liver disease and splenectomy in portopulmonary hypertension was not uncommon. History of splenectomy in patients with portal hypertension and/or autoimmune liver disease may have clinical implications.
门肺高压是门静脉高压的一种严重并发症,可导致右心衰竭和死亡。据我们所知,此前尚未描述过门肺高压与既往脾切除术之间的关联。本研究的目的是描述门肺高压患者中脾切除术的发生率,并比较门肺高压亚组之间的选定参数。
这是一项对1988年1月1日至2015年6月30日在美国明尼苏达州罗切斯特市梅奥诊所诊断为门肺高压的患者进行的回顾性分析。我们比较了有脾切除术和/或自身免疫性肝病(自身免疫性肝炎/原发性胆汁性肝硬化/原发性硬化性胆管炎)的门肺高压患者亚组之间的年龄、性别、经超声心动图测量的右心室收缩压以及右心导管检查测量值/计算值。
该队列由141名患者组成,其中8名(6%)在门肺高压发生之前有脾切除术史。27名(19%)门肺高压患者有自身免疫性肝病,8名脾切除的门肺高压患者中有5名(62.5%)有自身免疫性肝病。脾切除和未脾切除的门肺高压患者在右心导管检查测量值/计算值方面未发现显著差异。经超声心动图测量,脾切除患者的右心室收缩压明显更高。
在该队列中,门肺高压患者既往有脾切除术史的比例为6%。门肺高压患者中自身免疫性肝病与脾切除术并存并不少见。门静脉高压和/或自身免疫性肝病患者的脾切除术史可能具有临床意义。